Prospective clinical study of R-CMD therapy for indolent B-cell lymphoma and mantle cell lymphoma

Prospective clinical study of R-CMD therapy for indolent B-cell lymphoma and mantle cell lymphoma - R-CMD therapy for indolent B-cell lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001341

Enrollment

Registered

2008-09-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

indolent B-cell lymphoma, mantle cell lymphoma

Interventions

4 courses of R-CMD therapy (rituximab 375mg/m2, div on day1, Cladribine(2-CDA)0.10 mg/kg,2h div on day1-3, Mitoxantrone(MIT)8mg/m2,div on day1 and Dexamethasone8mg/body on day1-3) , 4 courses of ritux

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, indolent B-cell lymphoma(follicular lymphoma, marginal zone B-cell lymphoma, MALT, nodular and splenic type, lymphoplasmacytic lymphoma, etc) or mantle cell lymphoma 2, Adult, primary and Ann Arbor stage II-IV 3, informed consent

Exclusion criteria

Exclusion criteria: 1, low or negative expression CD20 2, severe infectious disease 3, Pre-treatment history for lymphoma 4, HIV+, HTLV1+, HBs-Ag+, HBc-Ab high titer 5, Pt who will be treat by allogenic or autologous stem cell transplantation 6, physician's decision of inappropriateness

Design outcomes

Primary

Measure	Time frame
CR rate	—

Secondary

Measure	Time frame
Adverse events, Overall survival, Overall response rate	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Hematology and Immunology

yasum@kanazawa-med.ac.jp076-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026